Synthistat Ltd

Meet Synthistat Ltd, developing next-generation synthetic HDAC inhibitors with the potential to tackle treatment-resistant cancers and improve the production of life-saving gene therapies. Co-founder Dr Zakeria Abdi explains the science, the potential impact for patients and the ambitions behind the company.